WC
KERX

Wexford Capital’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

Wexford Capital’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-97,017
Closed -$1.49M – 157
2014
Q2 		$1.49M Sell
97,017
-146,318
-60% -$2.07M 0.11% 75
2014
Q1 		$4.15M Sell
243,335
-181,145
-43% -$2.73M 0.31% 52
2013
Q4 		$5.5M Buy
424,480
+222,520
+110% +$2.66M 0.47% 31
2013
Q3 		$2.04M Buy
+201,960
New +$1.8M 0.17% 76

Other funds holding KERX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Wexford Capital's KERX Position: Q3 2014 in Review

Wexford Capital sold out of Keryx Biopharmaceuticals Inc (KERX) in Q3 2014, closing a stake of 97,017 shares — an estimated $1.49M sold.

Wexford Capital first reported a position in KERX in Q3 2013 and held it in 4 quarters. The position peaked at $5.5M in Q4 2013. 140 funds tracked by Wall St. Rank hold KERX as of Q3 2014.

  • Wexford Capital reported no remaining Keryx Biopharmaceuticals Inc position as of Q3 2014 after selling out during the quarter.
  • Wexford Capital sold 97,017 Keryx Biopharmaceuticals Inc shares in Q3 2014, an estimated $1.49M.
  • Wexford Capital first reported a position in Keryx Biopharmaceuticals Inc in Q3 2013 and held it in 4 quarters.
  • Wexford Capital's Keryx Biopharmaceuticals Inc position peaked at $5.5M in Q4 2013.
  • 140 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q3 2014.

Based on Wexford Capital's 13F filing for Q3 2014, filed 13 Nov 2014.